Cargando…
P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN’S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP).
Autores principales: | Gaudio, F., Loseto, G., Bozzoli, V., Scalzulli, P. R., Mazzone, A. M., Tonialini, L., Fesce, V., Quintana, G., De santis, G., Masciopinto, P., Arcuti, E., Clemente, F., Scardino, S., Tarantini, G., Pastore, D., Melillo, L., Pavone, V., Mazza, P., Carella, A. M., Cascavilla, N., Di Renzo, N., Guarini, A., Musto, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428959/ http://dx.doi.org/10.1097/01.HS9.0000847204.45147.68 |
Ejemplares similares
-
PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)
por: Mele, A., et al.
Publicado: (2022) -
P18: DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
por: Mele, G, et al.
Publicado: (2022) -
P17: DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE”
por: Mele, G, et al.
Publicado: (2022) -
Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”
por: Di Renzo, Nicola, et al.
Publicado: (2019) -
P1183: CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS AND AT RELAPSE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF THE “RETE EMATOLOGICA VENETA” (T-REV PROJECT).
por: Riva, Marcello, et al.
Publicado: (2023)